• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The exochelins of pathogenic mycobacteria: unique, highly potent, lipid- and water-soluble hexadentate iron chelators with multiple potential therapeutic uses.致病性分枝杆菌的外螯菌素:独特、高效、脂溶性和水溶性兼具的六齿铁螯合剂,具有多种潜在治疗用途。
Antioxid Redox Signal. 2014 Dec 1;21(16):2246-61. doi: 10.1089/ars.2013.5789. Epub 2014 Jun 20.
2
Lipophilic siderophores of Mycobacterium tuberculosis prevent cardiac reperfusion injury.结核分枝杆菌的亲脂性铁载体可预防心脏再灌注损伤。
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5263-8. doi: 10.1073/pnas.95.9.5263.
3
Exochelins of Mycobacterium tuberculosis remove iron from human iron-binding proteins and donate iron to mycobactins in the M. tuberculosis cell wall.结核分枝杆菌的外螯合素从人铁结合蛋白中去除铁,并将铁提供给结核分枝杆菌细胞壁中的分枝杆菌素。
J Exp Med. 1996 Apr 1;183(4):1527-32. doi: 10.1084/jem.183.4.1527.
4
Effect on ribonucleotide reductase of novel lipophilic iron chelators: the desferri-exochelins.新型亲脂性铁螯合剂(去铁外螯合素)对核糖核苷酸还原酶的影响
Biochem Biophys Res Commun. 2004 Mar 12;315(3):595-8. doi: 10.1016/j.bbrc.2004.01.101.
5
Iron acquisition by Mycobacterium tuberculosis: isolation and characterization of a family of iron-binding exochelins.结核分枝杆菌的铁摄取:一类铁结合外螯合素的分离与特性分析
Proc Natl Acad Sci U S A. 1995 May 23;92(11):5189-93. doi: 10.1073/pnas.92.11.5189.
6
Specificity of exochelins for iron transport in three species of mycobacteria.外排铁载体在三种分枝杆菌中对铁转运的特异性
J Gen Microbiol. 1980 Feb;116(2):521-3. doi: 10.1099/00221287-116-2-521.
7
Characterization of exochelins of the Mycobacterium bovis type strain and BCG substrains.牛分枝杆菌标准菌株和卡介苗亚菌株的外排螯合素特性分析。
Infect Immun. 1999 Apr;67(4):2035-9. doi: 10.1128/IAI.67.4.2035-2039.1999.
8
Extracellular iron acquisition by mycobacteria: role of the exochelins and evidence against the participation of mycobactin.分枝杆菌的细胞外铁获取:外螯合素的作用及反对分枝杆菌素参与的证据
Infect Immun. 1975 Dec;12(6):1242-51. doi: 10.1128/iai.12.6.1242-1251.1975.
9
Synthetic and natural iron chelators: therapeutic potential and clinical use.合成与天然铁螯合剂:治疗潜力与临床应用。
Future Med Chem. 2009 Dec;1(9):1643-70. doi: 10.4155/fmc.09.121.
10
Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.铁过载治疗的进展。去铁酮(L1)、去铁胺、新型实验性螯合剂ICL670、GT56 - 252、L1NA11及其组合的有效应用前景。
Curr Med Chem. 2005;12(23):2663-81. doi: 10.2174/092986705774463003.

引用本文的文献

1
Decoding the role of mycobacterial lipid remodelling and membrane dynamics in antibiotic tolerance.解析分枝杆菌脂质重塑和膜动力学在抗生素耐受性中的作用。
Chem Sci. 2024 Oct 29;15(45):19084-93. doi: 10.1039/d4sc06618a.
2
Yamaguchi esterification: a key step toward the synthesis of natural products and their analogs-a review.山口酯化反应:天然产物及其类似物合成的关键步骤——综述
Front Chem. 2024 Oct 11;12:1477764. doi: 10.3389/fchem.2024.1477764. eCollection 2024.
3
PPE37 Is Essential for Heme-Iron Acquisition (HIA), and a Defective PPE37 in BCG Prevents HIA.PPE37 对于血红素铁获取(HIA)至关重要,而缺陷型 PPE37 可阻止 BCG 中的 HIA。
Infect Immun. 2019 Jan 24;87(2). doi: 10.1128/IAI.00540-18. Print 2019 Feb.
4
A reevaluation of iron binding by Mycobactin J.重新评估分枝菌酸 J 的铁结合能力。
J Biol Inorg Chem. 2018 Oct;23(7):995-1007. doi: 10.1007/s00775-018-1592-2. Epub 2018 Jul 16.
5
Gallium Compounds Exhibit Potential as New Therapeutic Agents against Mycobacterium abscessus.镓化合物展现出作为抗脓肿分枝杆菌新治疗剂的潜力。
Antimicrob Agents Chemother. 2015 Aug;59(8):4826-34. doi: 10.1128/AAC.00331-15. Epub 2015 Jun 1.

本文引用的文献

1
IRP2 regulates breast tumor growth.IRP2 调控乳腺癌生长。
Cancer Res. 2014 Jan 15;74(2):497-507. doi: 10.1158/0008-5472.CAN-13-1224. Epub 2013 Nov 27.
2
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations.HIF-1 介导肿瘤内缺氧和致癌突变的代谢反应。
J Clin Invest. 2013 Sep;123(9):3664-71. doi: 10.1172/JCI67230. Epub 2013 Sep 3.
3
Discovery of a siderophore export system essential for virulence of Mycobacterium tuberculosis.发现一种铁载体输出系统对结核分枝杆菌的毒力至关重要。
PLoS Pathog. 2013 Jan;9(1):e1003120. doi: 10.1371/journal.ppat.1003120. Epub 2013 Jan 31.
4
MMS19 links cytoplasmic iron-sulfur cluster assembly to DNA metabolism.MMS19 将细胞质铁硫簇组装与 DNA 代谢联系起来。
Science. 2012 Jul 13;337(6091):243-5. doi: 10.1126/science.1219664. Epub 2012 Jun 7.
5
Formation of ultrafine deferasirox particles via rapid expansion of supercritical solution (RESS process) using Taguchi approach.通过田口法(Taguchi approach)利用超临界溶液快速膨胀(RESS 过程)形成超细去铁酮颗粒。
Int J Pharm. 2012 Aug 20;433(1-2):149-56. doi: 10.1016/j.ijpharm.2012.05.005. Epub 2012 May 11.
6
Lipidomic discovery of deoxysiderophores reveals a revised mycobactin biosynthesis pathway in Mycobacterium tuberculosis.脂质组学发现脱氧铁载体,揭示结核分枝杆菌中修订后的分枝菌酸生物合成途径。
Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):1257-62. doi: 10.1073/pnas.1109958109. Epub 2012 Jan 9.
7
Discovery and characterization of a unique mycobacterial heme acquisition system.发现并阐明一种独特的分枝杆菌血红素获取系统。
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5051-6. doi: 10.1073/pnas.1009516108. Epub 2011 Mar 7.
8
Iron-chelating therapy for transfusional iron overload.铁螯合疗法治疗输血引起的铁过载。
N Engl J Med. 2011 Jan 13;364(2):146-56. doi: 10.1056/NEJMct1004810.
9
An update on disordered iron metabolism and iron overload.铁代谢紊乱与铁过载的最新进展。
Hematology. 2010 Oct;15(5):311-7. doi: 10.1179/102453310X12647083621164.
10
Removal of Fe3+ and Zn2+ from plasma metalloproteins by iron chelating therapeutics depicted with SEC-ICP-AES.采用 SEC-ICP-AES 描绘铁螯合疗法从血浆金属蛋白酶中去除 Fe3+和 Zn2+。
Dalton Trans. 2010 Aug 28;39(32):7466-73. doi: 10.1039/c0dt00229a. Epub 2010 Jul 12.

致病性分枝杆菌的外螯菌素:独特、高效、脂溶性和水溶性兼具的六齿铁螯合剂,具有多种潜在治疗用途。

The exochelins of pathogenic mycobacteria: unique, highly potent, lipid- and water-soluble hexadentate iron chelators with multiple potential therapeutic uses.

作者信息

Horwitz Lawrence D, Horwitz Marcus A

机构信息

1 Division of Cardiology, Department of Medicine, University of Colorado Health Sciences Center , Denver, Colorado.

出版信息

Antioxid Redox Signal. 2014 Dec 1;21(16):2246-61. doi: 10.1089/ars.2013.5789. Epub 2014 Jun 20.

DOI:10.1089/ars.2013.5789
PMID:24684595
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4224048/
Abstract

SIGNIFICANCE

Exochelins are lipid- and water-soluble siderophores of Mycobacterium tuberculosis with unique properties that endow them with exceptional pharmacologic utility. Exochelins can be utilized as probes to decipher the role of iron in normal and pathological states, and, since they rapidly cross cell membranes and chelate intracellular iron with little or no toxicity, exochelins are potentially useful for the treatment of a number of iron-dependent pathological phenomena.

RECENT ADVANCES

In animal models, exochelins have been demonstrated to have promise for the treatment of transfusion-related iron overload, restenosis after coronary artery angioplasty, cancer, and oxidative injury associated with acute myocardial infarction and transplantation.

CRITICAL ISSUES

To be clinically effective, iron chelators should be able to rapidly enter cells and chelate iron at key intracellular sites. Desferri-exochelins, and other lipid-soluble chelators, can readily cross cell membranes and remove intracellular free iron; whereas deferoxamine, which is lipid insoluble, cannot do so. Clinical utility also requires that the chelators be nontoxic, which, we hypothesize, includes the capability to prevent iron from catalyzing free radical reactions which produce •OH or other reactive oxygen species. Lipid-soluble iron chelators currently available for clinical application are bidentate (deferiprone) or tridentate (desferasirox) molecules that do not block all six sites on the iron molecule capable of catalyzing free radical reactions. In contrast, desferri-exochelins are hexadentate molecules, and by forming a one-to-one binding relationship with iron, they prevent free radical reactions.

FUTURE DIRECTIONS

Clinical studies are needed to assess the utility of desferri-exochelins in the treatment of iron-dependent pathological disorders.

摘要

意义

外排螯合素是结核分枝杆菌的脂溶性和水溶性铁载体,具有独特的性质,赋予它们特殊的药理效用。外排螯合素可用作探针来解读铁在正常和病理状态下的作用,而且,由于它们能迅速穿过细胞膜并螯合细胞内铁,几乎没有或没有毒性,外排螯合素在治疗多种铁依赖性病理现象方面具有潜在用途。

最新进展

在动物模型中,外排螯合素已被证明在治疗输血相关铁过载、冠状动脉血管成形术后再狭窄、癌症以及与急性心肌梗死和移植相关的氧化损伤方面具有前景。

关键问题

为了在临床上有效,铁螯合剂应能够迅速进入细胞并在关键的细胞内位点螯合铁。去铁外排螯合素和其他脂溶性螯合剂能够轻易穿过细胞膜并去除细胞内游离铁;而脂不溶性的去铁胺则不能。临床效用还要求螯合剂无毒,我们推测这包括防止铁催化产生•OH或其他活性氧物质的自由基反应的能力。目前可用于临床的脂溶性铁螯合剂是双齿(去铁酮)或三齿(地拉罗司)分子,它们不能阻断铁分子上所有六个能够催化自由基反应的位点。相比之下,去铁外排螯合素是六齿分子,通过与铁形成一对一的结合关系,它们可防止自由基反应。

未来方向

需要进行临床研究以评估去铁外排螯合素在治疗铁依赖性病理疾病中的效用。